|
101 |
Completed
|
Doxil Topotecan Doublet Cancer Study
|
Conditions: |
Small Cell Lung Cancer; Pancreatic Cancer;
Head and Neck Cancer; Gastric Cancer;
Esophageal Cancer |
|
Intervention: |
Drug: Topotecan and pegylated doxorubicin |
|
|
102 |
Completed
|
Study of NGR-hTNF in Combination With
Doxorubicin in Solid Tumors
|
Condition: |
Cancer |
|
Intervention: |
Drug: NGR-hTNF |
|
|
103 |
Recruiting
|
Doxorubicin Hydrochloride Liposome as
First-Line Therapy in Treating Older Women With
Metastatic Breast Cancer
|
Condition: |
Breast Cancer |
|
Intervention: |
Drug: pegylated liposomal doxorubicin
hydrochloride |
|
|
104 |
Active, not
recruiting |
Vorinostat and Doxorubicin in Treating
Patients With Metastatic or Locally Advanced Solid
Tumors
|
Condition: |
Unspecified Adult Solid Tumor, Protocol Specific |
|
Interventions: |
Drug: doxorubicin hydrochloride; Drug: vorinostat;
Genetic: microarray analysis;
Other: laboratory biomarker analysis;
Other: pharmacological study;
Procedure: biopsy |
|
|
105 |
Active, not
recruiting |
Liposomal Doxorubicin and Docetaxel in
Metastatic Breast Cancer
|
Condition: |
Metastatic Breast Cancer |
|
Interventions: |
Drug: Pegylated liposomal doxorubicin;
Drug: Docetaxel |
|
|
106 |
Completed
|
A Study to Determine the Activity of
Caelyx With Trastuzumab and Docetaxel in the Treatment
of Metastatic Breast Cancer (Study P03679)(COMPLETED)
|
Condition: |
Breast Neoplasm |
|
Interventions: |
Drug: Pegylated Liposomal Doxorubicin;
Drug: Docetaxel; Drug: Trastuzumab |
|
|
107 |
Completed
|
Doxorubicin Hydrochloride Liposome and
Bortezomib in Treating Patients With Refractory
Hematologic Cancer or Malignant Solid Tumor or
Metastatic Breast Cancer
|
Conditions: |
Breast Cancer; Leukemia; Lymphoma;
Multiple Myeloma and Plasma Cell Neoplasm;
Ovarian Cancer;
Unspecified Adult Solid Tumor, Protocol Specific |
|
Interventions: |
Drug: bortezomib; Drug: pegylated liposomal
doxorubicin hydrochloride |
|
|
108 |
Recruiting
|
Topotecan, Vincristine, and Doxorubicin
in Treating Young Patients With Refractory Stage 4
Neuroblastoma
|
Condition: |
Neuroblastoma |
|
Interventions: |
Biological: filgrastim;
Drug: doxorubicin hydrochloride;
Drug: topotecan hydrochloride;
Drug: vincristine sulfate |
|
|
109 |
Recruiting
|
Study of CoQ10 During One Cycle of
Doxorubicin Treatment for Breast Cancer
|
Condition: |
Breast Cancer |
|
Interventions: |
Dietary Supplement: Coenzyme Q10;
Dietary Supplement: Coenzyme Q10 Placebo |
|
|
110 |
Recruiting
|
Doxorubicin Hydrochloride Liposome,
Melphalan, and Bortezomib in Treating Patients With
Relapsed or Refractory Stage I, Stage II, or Stage III
Multiple Myeloma
|
Condition: |
Multiple Myeloma and Plasma Cell Neoplasm |
|
Interventions: |
Drug: bortezomib; Drug: melphalan; Drug:
pegylated liposomal doxorubicin hydrochloride |
|
|
111 |
Suspended
|
Liposomal Doxorubicin, Vincristine, &
Dexamethasone Plus Arsenic Trioxide in Untreated
Symptomatic Multiple Myeloma
|
Condition: |
Multiple Myeloma |
|
Interventions: |
Drug: Pegylated Liposomal Doxorubicin (Doxil);
Drug: Vincristine; Drug: Dexamethasone (DVd);
Drug: Arsenic Trioxide (Trisenox) |
|
|
112 |
Completed
|
Doxorubicin and Carboplatin in Treating
Patients With Recurrent Ovarian Cancer
|
Condition: |
Ovarian Cancer |
|
Interventions: |
Drug: carboplatin;
Drug: doxorubicin hydrochloride |
|
|
113 |
Recruiting
|
Liposomal Doxorubicin Followed By
Bexarotene in Treating Patients With Cutaneous T-Cell
Lymphoma
|
Condition: |
Lymphoma |
|
Interventions: |
Drug: bexarotene; Drug: pegylated liposomal
doxorubicin hydrochloride |
|
|
114 |
Active, not
recruiting |
Patupilone Versus Doxorubicin in Patients
With Ovarian, Primary Fallopian, or Peritoneal Cancer
|
Conditions: |
Ovarian Cancer; Fallopian Tube Cancer;
Peritoneal Neoplasms |
|
Interventions: |
Drug: EPO906 (Patupilone); Drug: Doxil |
|
|
115 |
Active, not
recruiting |
Phase II Trial to Compare the Safety of
Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant
Therapy for HER2-positive Breast Cancer (Study
P05048AM2)
|
Condition: |
Breast Neoplasm |
|
Interventions: |
Drug: doxorubicin, cyclophosphamide, paclitaxel,
trastuzumab; Drug: PLD, cyclophosphamide,
trastuzumab, paclitaxel |
|
|
116 |
Terminated
|
DOXIL® vs. Xeloda® as First Line
Chemotherapy for Metastatic Breast Cancer in Women 60
Years and Older
|
Conditions: |
Breast Neoplasms; Cancer of Breast;
Breast Cancer; Cancer of the Breast |
|
Intervention: |
Drug: pegylated liposomal doxorubicin
hydrochloride (DOXIL®) or capecitabine
(Xeloda®) |
|
|
117 |
Recruiting
|
Vorinostat, Bortezomib, and Doxorubicin
Hydrochloride Liposome in Treating Patients With
Relapsed or Refractory Multiple Myeloma
|
Condition: |
Multiple Myeloma and Plasma Cell Neoplasm |
|
Interventions: |
Drug: bortezomib; Drug: pegylated liposomal
doxorubicin hydrochloride; Drug: vorinostat |
|
|
118 |
Recruiting
|
Dose-Escalation Study of TH-302 in
Combination With Doxorubicin to Treat Patients With
Advanced Soft Tissue Sarcoma
|
Condition: |
Soft Tissue Sarcoma |
|
Intervention: |
Drug: TH-302 |
|
|
119 |
Recruiting
|
Bortezomib, Doxorubicin Hydrochloride
Liposome, and Dexamethasone Followed by Thalidomide and
Dexamethasone With or Without Bortezomib in Treating
Patients With Multiple Myeloma
|
Condition: |
Multiple Myeloma and Plasma Cell Neoplasm |
|
Interventions: |
Drug: bortezomib; Drug: dexamethasone; Drug:
pegylated liposomal doxorubicin hydrochloride;
Drug: thalidomide |
|
|
120 |
Active, not
recruiting |
Rituximab and Liposomal Doxorubicin in
Treating Patients With Relapsed or Refractory
Non-Hodgkin's Lymphoma
|
Condition: |
Lymphoma |
|
Interventions: |
Biological: rituximab; Drug: pegylated
liposomal doxorubicin hydrochloride |
|
